Skip to main content
. 2011 Apr 5;19(8):1558–1568. doi: 10.1038/mt.2011.29

Figure 4.

Figure 4

Decreased vascular endothelial growth factor (VEGF) expression and angiogenesis in tumors treated with combination therapy. Tumors were treated with phosphate-buffered saline (PBS), dendritic cells (DCs), Ad-ΔB7/IL12/GMCSF, Ad-ΔB7/IL12/GMCSF plus DCs, or Ad-ΔB7/IL12/GMCSF (H; high-dose of Ad) plus DCs, and harvested from mice at 3 days after final treatment. (a) The level of VEGF expression in tumor tissues was quantified by conventional enzyme-linked immunosorbent assay. *P < 0.05. (b) CD31+ microvessel immunohistochemistry in the tumor tissues treated with PBS, DC, Ad-ΔB7/IL12/GMCSF, Ad-ΔB7/IL12/GMCSF plus DCs, or Ad-ΔB7/IL12/GMCSF (H) plus DCs. Original magnification: ×100 and ×400. (c) The means of CD31+ vessel density in microscopic field for each treatment group (×200). Data points represent the mean ± SE of three mice per group, and similar results were obtained from at least two separate experiments. *P < 0.05; **P < 0.01. GM-CSF, granulocyte-macrophage colony-stimulating factor; IL, interleukin.